Terumo Corporation
4543.THealthcareTSEMedical Instruments & Supplies · Last scanned May 30, 2026
Scan Results
Daily timeframeTerumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. Valued at $3.54T, 4543.T is a mega-cap name in its sector. The company operates through four segments: Cardiac and Vascular Company, Medical Care Solutions Company, Blood and Cell Technologies Company, and Terumo Organ Technologies.
Market Cap
$3.54T
Beta
0.18
P/E (TTM)
25.99
P/E (Fwd)
23.58
EPS (TTM)
$92.20
EPS (Fwd)
$101.83
ROE
9.2%
ROA
5.7%
Cash
$280.49B
Total Debt
$428.02B
Free CF
$64.11B
52W Change
-8.5%
Annual Financials
Cash vs Debt
The company holds $280.49B in cash, though total debt stands at $428.02B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $64.11B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 9.2%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.7% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $703.30B (2022) to $1.04T (2025), reflecting a 47% increase over the period.
With a beta below 0.7, Terumo Corporation typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Terumo Corporation and its sector.